Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT04848025
Collaborator
(none)
30
1
1
28.9
1

Study Details

Study Description

Brief Summary

Airway stenting is usually efficient to treat central airway obstruction but can lead to severe and potentially lethal complications (stent migration, obstructive granuloma, perforation, and hemoptysis).

3D customized airway stents (computer-aided conception using CT-scan data), perfectly suited to airway anatomy, should improve the tolerance and safety of airway stenting.

We demonstrated in a previous pilot study, dedicated to patients with anatomically complex stenoses the safety of 3D patient-specific stents. These appealing results in highly complex situations suggest the need to evaluate these devices in more common situations.

In this study we aim to test our new generation stents in all patients planned for airway stenting. After computer-assisted segmentation of airways (VGStudioMAX 3.0 software), the stenosis is virtually corrected, leading to the conception of a virtual stent (AnatomikModeling, Toulouse), allowing for the fabrication of a mold using a 3D printer. The stent is then built and sterilized (NOVATECH, Berlin) and inserted during rigid bronchoscopy.

Close follow up is then conducted, including clinical evaluation after one week, three, six and 12 months; spirometry at one week, 3 months, 6 months and 12 months and chest CT-scan at one week.

Condition or Disease Intervention/Treatment Phase
  • Device: Custom-designed tracheobronchial prostheses
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM (Three-dimensional Airway Tailored Stent Using Computer-aided Modeling)
Actual Study Start Date :
Jun 17, 2021
Anticipated Primary Completion Date :
Nov 15, 2023
Anticipated Study Completion Date :
Nov 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3D customized airway stents

Device: Custom-designed tracheobronchial prostheses
Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia

Outcome Measures

Primary Outcome Measures

  1. Percentage of procedures with clinical improvement of the dyspnea [12 months]

    Percentage of procedures with clinical improvement of the dyspnea with questionnaires of Borg, MMRC, and Dyspnea 12

  2. Percentage of procedures with clinical improvement of quality of life [12 months]

    Percentage of procedures with clinical improvement of quality of life with the VQ11 questionnaire

Secondary Outcome Measures

  1. Percentage of procedures with functional improvement [1 seconde]

    Percentage of procedures with functional improvement ( forced expiratory volume in one second (FEV1))

  2. Percentage of procedures with congruence of the stent [1 week]

    Percentage of procedures with congruence of the stent with tracheobronchial anatomy on CT-scan at 1 week

  3. Percentage of procedures without complications [12 months]

    Percentage of procedures without complications at 1 week, 3 months, 6 months and 12 months (stent migration, obstructive granuloma, perforation, hemoptysis).

  4. Percentage of procedures with clinical and functional improvement [12 months]

    Percentage of procedures with clinical (dyspnea, cough, quality of life (VQ11 questionnaire)), and functional improvement (peak flow, forced expiratory volume in one second (FEV1)) at 3 months, 6 months and 12 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age >18 years

  • Informed consent

  • Complex, proximal and symptomatic (dyspnea, cough, peak flow < 50%, FEV1 < 50% or post-stenotic infection) airway stenosis

Exclusion Criteria:
  • Acute respiratory distress, mechanical ventilation

  • Contraindication to rigid bronchoscopy (severe and irreversible coagulation disorders)

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Toulouse Toulouse France 31000

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Nicolas GUIBERT, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT04848025
Other Study ID Numbers:
  • RC31/19/0052
First Posted:
Apr 19, 2021
Last Update Posted:
Nov 4, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 4, 2021